2022
Once-Weekly Exenatide in Youth With Type 2 Diabetes
Tamborlane WV, Bishai R, Geller D, Shehadeh N, Al-Abdulrazzaq D, Vazquez EM, Karoly E, Troja T, Doehring O, Carter D, Monyak J, Sjöström CD. Once-Weekly Exenatide in Youth With Type 2 Diabetes. Diabetes Care 2022, 45: 1833-1840. PMID: 35679098, PMCID: PMC9346995, DOI: 10.2337/dc21-2275.Peer-Reviewed Original ResearchConceptsType 2 diabetesEfficacy end pointWeekly exenatideAdverse eventsPlacebo groupPrimary efficacy end pointSecondary efficacy end pointsEnd pointMetformin monotherapyTreatment of youthInsulin therapyWeek 24Pediatric patientsWeekly injectionsDaily injectionsGlycated hemoglobinCurrent treatmentExenatideBody weightDiabetesLiraglutideWeeksHemoglobinTreatmentBaseline
2019
Liraglutide in Children and Adolescents with Type 2 Diabetes
Tamborlane WV, Barrientos-Pérez M, Fainberg U, Frimer-Larsen H, Hafez M, Hale PM, Jalaludin MY, Kovarenko M, Libman I, Lynch JL, Rao P, Shehadeh N, Turan S, Weghuber D, Barrett T. Liraglutide in Children and Adolescents with Type 2 Diabetes. New England Journal Of Medicine 2019, 381: 637-646. PMID: 31034184, DOI: 10.1056/nejmoa1903822.Peer-Reviewed Original ResearchConceptsGlycated hemoglobin levelsType 2 diabetesGastrointestinal adverse eventsAdverse eventsPlasma glucose levelsHemoglobin levelsEnd pointGlycemic controlGlucose levelsMean glycated hemoglobin levelOpen-label extension periodPrimary efficacy end pointDose of liraglutideDouble-blind periodEfficacy end pointPrimary end pointSecondary end pointsBody mass indexNumber of patientsYears of ageMetformin monotherapySubcutaneous liraglutidePlacebo groupLiraglutide groupInclusion criteria
2015
Effect of Metformin Added to Insulin on Glycemic Control Among Overweight/Obese Adolescents With Type 1 Diabetes: A Randomized Clinical Trial
Libman IM, Miller KM, DiMeglio LA, Bethin KE, Katz ML, Shah A, Simmons JH, Haller MJ, Raman S, Tamborlane WV, Coffey JK, Saenz AM, Beck RW, Nadeau KJ. Effect of Metformin Added to Insulin on Glycemic Control Among Overweight/Obese Adolescents With Type 1 Diabetes: A Randomized Clinical Trial. JAMA 2015, 314: 2241-2250. PMID: 26624824, DOI: 10.1001/jama.2015.16174.Peer-Reviewed Original ResearchConceptsType 1 diabetesBody mass indexGastrointestinal adverse eventsEffect of metforminTotal daily insulinGlycemic controlPlacebo groupOverweight adolescentsMetformin groupBaseline HbA1cAdverse eventsDaily insulinClinical trialsMultiple secondary end pointsOverweight/obese adolescentsSafety of metforminSecondary end pointsUse of metforminAddition of metforminBMI z-scoreMeasures of adipositySecondary outcomesBlood pressureInsulin dosePrimary outcome
2008
Short‐term metabolic and cardiovascular effects of metformin in markedly obese adolescents with normal glucose tolerance
Burgert TS, Duran EJ, Goldberg‐Gell R, Dziura J, Yeckel CW, Katz S, Tamborlane WV, Caprio S. Short‐term metabolic and cardiovascular effects of metformin in markedly obese adolescents with normal glucose tolerance. Pediatric Diabetes 2008, 9: 567-576. PMID: 18761646, DOI: 10.1111/j.1399-5448.2008.00434.x.Peer-Reviewed Original ResearchConceptsNormal glucose toleranceInsulin sensitivityGlucose toleranceObese childrenDouble-blind clinical trialType 2 diabetes mellitusSubcutaneous fatCardio-metabolic consequencesBaseline insulin sensitivityImproved insulin sensitivityInsulin-resistant adolescentsHeart rate recoveryLong-term treatmentDeep subcutaneous fatShort-term useMagnetic resonance imagingPlacebo groupCardiovascular effectsDiabetes mellitusMetS groupClinical effectsLipid parametersInsulin sensitizersInflammatory cytokinesObese adolescents